Clinical Trial Update: Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update reports results for the paliperidone palmitate 3-month and 1-month formulations in schizophrenia. Results were posted in May …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA SUSTENNA (PALIPERIDONE PALMITATE)
• Invega Trinza (paliperidone palmitate)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2016-05-02